Physician profile
Roger Muller
NPI 1205912581
$75,054.27
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $60K · 2020: $9,427 · 2021: $6,070.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eli Lilly and Company | $20,331.13 | 2019-2020 | |
| Celgene Corporation | $10,196.71 | 2019 | |
| Janssen Pharmaceuticals, INC | $7,306.14 | 2019-2020 | |
| Lilly USA, LLC | $6,976.28 | 2019 | |
| Genentech USA, INC. | $5,901.67 | 2019 | |
| Amgen INC. | $5,200.00 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $3,950.00 | 2021 | |
| Mylan Specialty L.P. | $3,530.29 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $3,222.01 | 2019-2020 | |
| Mylan Institutional INC. | $2,407.54 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $2,120.00 | 2021 | |
| Amarin Pharma, INC. | $1,750.00 | 2019 | |
| Mdd US Operations, LLC | $1,750.00 | 2019 | |
| Cepheid | $412.50 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roger Muller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.